海南医科大学学报

目的:观察诺和龙的降糖效果及在控制血糖的情况下,发生低血糖的情况。方法:将124例2型糖尿病患者随机分成3组,A组单独采用诺和龙治疗,B组与二甲双胍联合治疗,C组与α糖苷酶抑制剂联合治疗。观察各组治疗对2型糖尿病患者血糖控制的影响,疗程共12周。结果:单用诺和龙组,空腹血糖平均下降23.5%,餐后2h血糖平均下降32.6%,与α糖苷酶抑制剂联合治疗组空腹血糖平均下降15.7%,餐后2h血糖平均下降29.8%,与二甲双胍联合治疗组空腹血糖平均下降21.8%,餐后2h血糖平均下降32.5%。结论:诺和龙单独用药,还是联合用药,均可显著降低2型糖尿病患者的空腹血糖及餐后血糖。且未见低血糖和其他严重不良反应。

Objective:To investigate the effects of repaglinide on type 2 diabetes and side effects of hypoglycemia.Methods:One hundred and twenty-four patients with type 2 diabetes were divided randomly into 3 groups,patients in group A were treated with repaglinide,patients in group B were treated with repaglinide and metformin,and patients in group C were treated with repaglinide and α glucosidase inhibitor;the therapy course was 12 weeks;effect of blood glucose control and side effects were observed and compared.Results:Avarage fasting blood glucose 2 hours postprandial blood glucose decrease in patients of group A,B and C were 23.5%,32.6% and 21.8%,32.5 % and 15.7%,29.8 % respectively.Conclusion:Repaglinide alone or combined with other medication can significantly lower fasting blood glucose and postprandial blood glucose of patients with type 2 diabetes,and no hypoglycemia and other serious adverse reactions occure.